Used in the treatment of cold agglutinin disease (CAD), this antibody selectively targets and inhibits the C1s protein in the classical complement pathway. By blocking this pathway, it prevents the destruction of red blood cells, reducing hemolysis and the need for blood transfusions. It is administered intravenously and helps stabilize hemoglobin levels in affected patients, improving quality of life and reducing disease-related complications.